


Saturday, October 17, 2026

Philadelphia Marriott Old City, One Dock Street, Philadelphia, PA 19106

Philadelphia Lung Cancer Symposium: Clinical Updates for 2026

Hosted by Fox Chase Cancer Center in Collaboration
with Penn Medicine Abramson Cancer Center



This multidisciplinary symposium features expert faculty from leading healthcare institutions who will review evolving standards in early-stage disease, small cell lung cancer, targeted therapies, and emerging strategies shaping practice in 2026 and beyond.

Learning Objectives

- Provide an update on the most recent changes in the treatment of lung cancer
- Explain the rationale and need for HER2 testing and HER2-directed treatment
- Describe the use of bispecific antibodies in lung cancer treatment

Intended Audience

- Physicians and trainees
- Nurses
- Advanced practice providers
- Rehabilitation specialists and genetic counselors
- Pharmacy, radiology, and pathology professionals
- Patient navigators and other healthcare professionals involved in lung cancer care

INQUIRIES


Lucía Tono, PhD, MEd Lucia.Tono-Ramirez@tuhs.temple.edu

ACCREDITATION STATEMENT: The Temple Health Office for Continuing Medical Education is accredited by the Pennsylvania Medical Society to provide continuing medical education for physicians. Fox Chase Cancer Center is approved as a provider of nursing continuing professional development by the Pennsylvania State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

DESIGNATION STATEMENT: The Temple Health Office for Continuing Medical Education designates this live activity for a maximum of 6 AMA PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the educational activity. Fox Chase Cancer Center designates this live activity for a maximum of 6 Hour(s) NCPD (ANCC Contact Hours). Participants should claim only the credit commensurate with the extent of their participation in the activity.

ABS MOC STATEMENT: Successful completion of this CME activity enables the learner to earn credit toward the CME requirement of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

Program Directors



Hossein Borghaei, DO, MS

*Interim Chair & Professor,
Department of Hematology/Oncology
Chief, Division of Thoracic Medical Oncology
Co-Director, Immune Monitoring Facility
Gloria and Edmund M. Dunn Chair
in Thoracic Oncology,
Fox Chase Cancer Center*



Charu Aggarwal, MD, MPH, FASCO

*Section Chief, Head & Neck and Thoracic Cancers,
Hematology/Oncology
Director, Precision Oncology Innovation,
Penn Center for Cancer Care Innovation
Physician Leader, Airways Malignancies Research
Leslye M. Heisler Professor
for Lung Cancer Excellence
Penn Medicine's Abramson Cancer Center*

Planning Advisor



Michael Seidman, MD

*Professor, Department of Hematology/Oncology
Director, Hematology/Oncology Network Sites
Fox Chase Cancer Center*




Scan to access interactive agenda
with links to speaker profiles and
lung cancer physician resources.

Schedule and Agenda

CHECK-IN, BREAKFAST & EXHIBITS OPEN
(7:15 AM – 8 AM)

WELCOME & OPENING REMARKS
(8 AM – 8:10 AM)



Hossein Borghaei, DO, MS

*Interim Chair & Professor,
Department of Hematology/Oncology
Chief, Division of Thoracic Medical Oncology
Co-Director, Immune Monitoring Facility
Gloria and Edmund M. Dunn Chair
in Thoracic Oncology,
Fox Chase Cancer Center*



Charu Aggarwal, MD, MPH, FASCO

*Section Chief,
Head & Neck and Thoracic Cancers,
Hematology/Oncology
Director, Precision Oncology Innovation,
Penn Center for Cancer Care Innovation
Physician Leader,
Airways Malignancies Research
Leslye M. Heisler Professor
for Lung Cancer Excellence
Penn Medicine's Abramson Cancer Center*

**SESSION 1 – EARLY-STAGE NON-SMALL
CELL LUNG CANCER**
(8:10 AM – 9:50 AM)

Perioperative Chemotherapy-Immunotherapy for Early-Stage NSCLC



KEYNOTE SPEAKER

Corey J. Langer, MD

*Director, Thoracic Oncology
Professor of Medicine (Hematology/Oncology)
at the Hospital of the University of Pennsylvania
Penn Medicine's Abramson Cancer Center*

Perioperative Targeted Therapy for Early-Stage NSCLC



Jingxiao Jin, MD

*Assistant Professor,
Department of Hematology/Oncology
Fox Chase Cancer Center*

Surgical Perspectives in the Management of Early-Stage NSCLC



Katherine Gray, MD

*Assistant Attending Physician
Thoracic Surgery
Memorial Sloan Kettering Cancer Center*

Radiation Oncology Approaches for Early-Stage NSCLC



Sameera Kumar, MD

*Associate Professor,
Department of Radiation Oncology
Fox Chase Cancer Center*

Multidisciplinary Tumor Board Cases: Perspectives From Surgery, Pathology, Interventional Pulmonology, Radiology, Medical Oncology and Radiation Oncology

(9:10 AM – 9:50 AM)



Lisa A. Bevilacqua, MD

*Assistant Professor,
Department of Surgery
Fox Chase Cancer Center*



Steven Joel Feigenberg, MD

*Chief, Thoracic Service, Radiation Oncology
Professor of Radiation Oncology at the
Hospital of the University of Pennsylvania
Penn Medicine's Abramson Cancer Center*



Douglas B. Flieder, MD

*Professor and Chair,
Department of Pathology
Director, Surgical Pathology
Fox Chase Cancer Center*



Sarah W. Gordon, DO

*Associate Professor,
Thomas Jefferson University
Lung Program Leader,
Jefferson Health Enterprise
Director Phase 1 Program/Early Drug
Development Office,
Sidney Kimmel Comprehensive Cancer Center*

EXHIBITOR BREAK (9:50AM – 10:10AM)

SESSION II: SMALL CELL LUNG CANCER & EMERGING APPROACHES (10:10 AM – 12:10 PM)

Limited-Stage Small Cell Lung Cancer



Parth A. Desai, MBBS, MD

Assistant Professor,
Department of Hematology/Oncology
Director, Clinical and Translational Research,
Thoracic and Head & Neck Service Lines
Fox Chase Cancer Center

Extensive-Stage Small Cell Lung Cancer



Sukhmani Kaur Padda, MD

Vice Chair of Medical Oncology,
Fox Chase Cancer Center
Professor, Clinical Investigator Track,
Thoracic and Phase I Oncology
Fox Chase Cancer Center

Neuroendocrine Cancers and Management



Martin J. Edelman, MD, FACP

Professor, Department of Hematology/Oncology
Associate Cancer Center Director
for Clinical Research Integration
G. Morris Dorrance Jr. Chair in Medical Oncology
Fox Chase Cancer Center

Community Oncology Panel Discussion (11:00 AM – 11:15 AM)



Deric C. Savior, MD, FCPP

Medical Director,
Main Line Health Cancer Care Services
Chief, Medical Oncology, Lankenau Medical Center
Hematology/Oncology, Main Line Health System



Sukhmani Kaur Padda, MD

Vice Chair of Medical Oncology,
Fox Chase Cancer Center
Professor, Clinical Investigator Track,
Thoracic and Phase I Oncology
Fox Chase Cancer Center



Michael Seidman, MD


Professor, Department of Hematology/Oncology
Director, Hematology/Oncology Network Sites
Fox Chase Cancer Center



Jennifer S. Winn, MD, MS

Associate Professor,
Department of Hematology/Oncology
Fox Chase Cancer Center

Antibody-Drug Conjugates



Benjamin A. Bleiberg, MD

Assistant Professor,
Department of Hematology/Oncology
Fox Chase Cancer Center

Bispecific Antibodies



Melina Elpi Marmarelis, MD

Medical Director, Penn Mesothelioma Program
Associate Professor of Medicine
(Hematology/Oncology) at the Hospital of the
University of Pennsylvania
Penn Medicine's Abramson Cancer Center

ctDNA/MRD



KEYNOTE SPEAKER

Christian Diego Rolfo, MD, PhD

Director of the Division of Medical Oncology
The Ohio State University
Comprehensive Cancer Center – The James
Professor, Internal Medicine
The Ohio State University College of Medicine

Advanced Practice Provider Panel (11:55 AM – 12:10 PM)



Justin Eppley, DNP, CRNP, AGPCNP-BC

Advanced Practice Provider
Fox Chase Cancer Center



Kaitlyn Gregory, DNP, CRNP, FNP-BC

Advanced Practice Provider
Fox Chase Cancer Center

EXHIBITOR BREAK & LUNCH (12:10 PM – 1:10 PM)

Guest Advocacy Group: **Ride Hard Breathe Easy**



Scan to access interactive agenda
with links to speaker profiles and
lung cancer physician resources.

SESSION III: TARGETED THERAPY (1:10 PM – 3:30 PM)

First-Line Treatment of EGFR-Mutant NSCLC



Charu Aggarwal, MD, MPH, FASCO

Section Chief, Head & Neck and Thoracic Cancers,
Hematology/Oncology
Director, Precision Oncology Innovation,
Penn Center for Cancer Care Innovation
Physician Leader, Airways Malignancies Research
Leslye M. Heisler Professor
for Lung Cancer Excellence
Penn Medicine's Abramson Cancer Center

EGFR-Mutant NSCLC: Second Line and Beyond



Gregory J. Riely, MD, PhD

Ning Zhao and Ge Li Chair in Lung Cancer Research
Vice Chair of Clinical Research,
Department of Medicine
Memorial Sloan Kettering Cancer Center

Updates in ALK- and ROS1-Positive NSCLC



Jessica Bauman, MD

Chief, Division of Head and Neck Medical Oncology
Associate Professor,
Department of Hematology/Oncology
Director, Hematology/Oncology Fellowship
Training Program
Fox Chase Cancer Center

Updates in HER2-Mutant/IHC-Positive NSCLC



Jenny O'Brien, MD, PhD

Assistant Professor,
Department of Hematology/Oncology
Fox Chase Cancer Center


Updates in KRAS-Mutant NSCLC



Kathryn C. Arbour, MD

Thoracic Medical Oncologist
Assistant Attending Physician
Memorial Sloan Kettering Cancer Center

MET/BRAF-Altered NSCLC



Veli Bakalov, MD

Assistant Professor of Medicine,
Cooper Medical School of Rowan University
Hematologist/Oncologist,
Cooper Norcross University Hospital

Case-Based Multidisciplinary Panel Discussion (2:30 PM – 3:10 PM)



Jason A. Damsker, MD, FACP

Professor, Department of Hematology/Oncology
Fox Chase Cancer Center



Leah Holben, MD

Assistant Professor,
Department of Hematology/Oncology
Fox Chase Cancer Center



Michael Seidman, MD

Professor, Department of Hematology/Oncology
Fox Chase Cancer Center
Director, Hematology/Oncology Network Sites
Fox Chase Cancer Center



Aditi P. Singh, MD

Associate Professor of Clinical Medicine
Director of Clinical Informatics
and Operations Integration –
Division of Hematology and Oncology
Abramson Cancer Center/University
of Pennsylvania

CLOSING REMARKS (3:10 PM)

Exhibitors

PRESENTING

Johnson & Johnson

GOLD

Boehringer Ingelheim Daiichi Sankyo

SILVER

AbbVie Bayer
AstraZeneca Pharmacosmos

BRONZE

Amgen	Exelixis	Incyte Corporation
Bristol Myers	Foundation	Merck
Squibb	Medicine	Nuvation Bio
Caris	Genentech	Pfizer
EMD Serono	Guardant Health	Regeneron